Frazier stretches skill set to public arena with $830M fund

After devoting small portions of its last three funds to public investing, Frazier is jumping deeper into that arena with an $830 million vehicle dedicated solely to investing in publicly traded biotechs.

Frazier Healthcare Partners said Thursday it has closed the Frazier Life Sciences Public Fund, an oversubscribed, long-only, evergreen fund. It will take positions in about 30-40 biotechs, Managing Partner Albert Cha told BioCentury...